Table 4 Factors affecting the relapse/refractory (R/R) rate
Not R/R (n = 61) | R/R (n = 19) | P value | |
|---|---|---|---|
Age (years) | |||
< 5 years (n = 3) | 3 (4.2%) | 0 (0.0%) | 0.061 |
5–9.99 years (n = 23) | 21 (34.4%) | 2 (10.5%) | |
≥ 10–16 years (n = 54) | 37 (60.7%) | 17 (89.5%) | |
Gender | |||
Female (n = 35) | 26 (42.6%) | 9 (47.4%) | 0.716 |
Male (n = 45) | 35 (57.4%) | 10 (52.6%) | |
B symptoms | |||
No (n = 46) | 39 (63.9%) | 7 (36.8%) | 0.037* |
Yes (n = 34) | 22 (36.1%) | 12 (63.2%) | |
Primary site | |||
Peripheral lymph nodes (n = 65) | 51 (83.6%) | 14 (73.7%) | 0.422 |
Mediastinum (n = 15) | 10 (16.4%) | 5 (26.3%) | |
Bulky | |||
No (n = 59) | 45 (73.8%) | 14 (73.7%) | 0.994 |
Yes (n = 21) | 16 (26.2%) | 5 (26.3%) | |
Extra nodal involvement | |||
No (n = 51) | 40 (65.6%) | 11 (57.9%) | 0.543 |
Yes (n = 29) | 21 (34.4%) | 8 (42.1%) | |
Pathology | |||
cHL, nodular sclerosis (n = 44) | 35 (57.4%) | 9 (47.4%) | 0.827 |
cHL, mixed cellularity (n = 18) | 13 (21.3%) | 5 (26.3%) | |
cHL, lymphocyte rich (n = 9) | 6 (9.8%) | 3 (15.8%) | |
NLPHL (n = 9) | 7 (11.5%) | 2 (10.5%) | |
Stage | |||
Early (I, II) (n = 30) | 26 (42.6%) | 4 (21.1%) | 0.090 |
Advanced (III, IV) (n = 50) | 35 (57.4%) | 15 (78.9%) | |
Risk group | |||
Low (n = 12) | 11 (18.0%) | 1 (5.3%) | 0.009* |
Intermediate (n = 44) | 37 (60.7%) | 7 (36.8%) | |
High (n = 24) | 13 (21.3%) | 11 (57.9%) | |